Entero Therapeutics Files 2024 10-K
Ticker: GRDX · Form: 10-K · Filed: Apr 1, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 10-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Entero Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Entero Therapeutics, Inc. filed its 2024 10-K on April 1, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly known as First Wave BioPharma, Inc., is based in Boca Raton, FL. Key financial figures and operational details for the period are outlined in the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Entero Therapeutics' financial health and operational status for the fiscal year 2024, including any significant changes or risks.
Risk Assessment
Risk Level: medium — The filing is a standard annual report, but the company's history of name changes and its industry (pharmaceutical preparations) suggest inherent risks.
Key Numbers
- 4754038 — Total Assets (Reported for the fiscal year ending 2024-12-31)
- 1560998 — Total Liabilities (Reported for the fiscal year ending 2024-12-31)
- 514.96 — Revenue (Reported for the fiscal year ending 2024-12-31)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-04-01 (date) — Filing date
- Boca Raton, FL (location) — Company business address
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
FAQ
What were Entero Therapeutics' total assets as of December 31, 2024?
As of December 31, 2024, Entero Therapeutics, Inc. reported total assets of $4,754,038.
What were the company's total liabilities for the fiscal year ending December 31, 2024?
The total liabilities for Entero Therapeutics, Inc. as of December 31, 2024, were $1,560,998.
What was the reported revenue for Entero Therapeutics in the fiscal year ending December 31, 2024?
Entero Therapeutics, Inc. reported revenue of $514.96 for the fiscal year ending December 31, 2024.
When was Entero Therapeutics, Inc. previously known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
What is the business address of Entero Therapeutics, Inc.?
The business address for Entero Therapeutics, Inc. is 777 Yamato Road, Suite 502, Boca Raton, FL 33431.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 1, 2025 regarding Entero Therapeutics, Inc. (GRDX).